![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vetoquinol (PK) | USOTC:VETOF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 55.53 | 0.01 | 602.46 | 0.00 | 21:00:04 |
The Committee for Medicinal Products for Veterinary Use, or CVMP, said Friday it adopted by consensus a positive opinion for a marketing authorization application for Cimalgex, cimicoxib, from Vetoquinol SA (VETOF), for the treatment of pain and inflammation associated with osteoarthritis, and the management of peri-operative pain due to orthopedic or soft tissue surgery, in dogs.
MAIN FACTS:
-Committee adopted by consensus a positive opinion for a marketing authorization application for Comfortis, spinosad, from Eli Lilly and Company Ltd (LLY), for the treatment and prevention of flea infestations in dogs.
-Committee adopted by consensus a positive opinion for a marketing authorization application for ACTIVYL, indoxacarb, from Intervet International BV, for the treatment and prevention of flea infestations in cats and dogs.
-Committee adopted by consensus a positive opinion for a marketing authorization application for Purevax Rabies from MERIAL, for the active immunization of cats to prevent mortality due to rabies infection.
-Committee adopted by consensus a positive opinion for a marketing authorization application for Melosus, meloxicam, from CP-Pharma Handelsgesellschaft mbH, for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs and the alleviation of inflammation and pain in chronic musculo-skeletal disorders in cats.
-Committee adopted by consensus a positive opinion for a type II variation application for Zulvac 8 Ovis and ZOLVIX.
-Committee also adopted by consensus a negative opinion for a type II variation application for Masivet.
-Committee agreed scientific advice concerning the establishment of an MRL for horses as a follow-up request to advice previously given.
-Committee also agreed scientific advice for review of dossier requirements in line with the MUMS guidelines for an immunological product for sheep and goats.
-By Tapan Panchal, Dow Jones Newswires. Tel +44(0)207-842 9448, tapan.panchal@dowjones.com
1 Year Vetoquinol (PK) Chart |
1 Month Vetoquinol (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions